→ Regeneron and Ionis each have publications in The New England Journal of Medicine aimed at a brand new cardio target ANGPTL3. The New York Times chronicles the story, which begins in 1994 when a woman in St. Louis gave a blood sample at an employer-sponsored health fair. Regeneron is working on a monoclonal antibody which they say has reduced atherosclerotic lesions in mice and lowered triglycerides and LDL in humans. Ionis is going after the same target using an antisense oligonucleotide targeting Angptl3 messenger RNA. They say they observed dose-dependent reductions in triglycerides and LDL, slowing of atherosclerosis progression and an increase in insulin sensitivity in mice that received the compound. Human participants who received weekly injections of the oligonucleotide had triglyceride reductions ranging from 33% to 63%, LDL reductions ranging from 1% to 33%, VLDL reductions of 28%-60%, and non-HDL level reductions of 10% to 36.6%.
→ Taiwan’s Aslan Pharmaceuticals raised $33 million from an IPO on the Taipei Exchange. In August, the company struck a deal with Bristol-Myers Squibb for $10 million up front followed by $50 million in milestones plus royalties for their c-MET inhibitor. Aslan focuses on therapies for Asia-prevalent tumour types.
→ Redx shares were suspended after the city of Liverpool said the biotech went delinquent on a £2m loan granted five years ago. The company has since relocated to Cheshire, and claims that they have been in discussions with Liverpool about the payment of the loan. But Joe Anderson, the city’s mayor, said: “Even at the eleventh hour the city council was willing to work on a repayment schedule, but it is now clear Redx has no intention to work with us in any meaningful way.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription